NEW YORK, July 26 – Sensium Technologies has expanded its license to protein biochip technology from the University of Alberta and Canadian technology transfer company PENCE, Sensium said Thursday.

Sensium, the proteomics subsidiary of Aurora, Ontario-based biopharmaceutical company Helix BioPharma, will now be able to use the technology exclusively in drug discovery, as well as in other applications. The original license dates from 1996.